Medistim Future Growth

Future criteria checks 2/6

Medistim is forecast to grow earnings and revenue by 7.5% and 4.6% per annum respectively while EPS is expected to grow by 7.4% per annum.

Key information

7.5%

Earnings growth rate

7.4%

EPS growth rate

Medical Equipment earnings growth	18.3%
Revenue growth rate	4.6%
Future return on equity	n/a
Analyst coverage	Low
Last updated	26 Apr 2024

Recent future growth updates

Medistim ASA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 04

Recent updates

Medistim ASA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 04

Is Medistim ASA's(OB:MEDI) Recent Stock Performance Tethered To Its Strong Fundamentals?

Mar 19

Medistim ASA (OB:MEDI) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 02

Here's What You Should Know About Medistim ASA's (OB:MEDI) 1.1% Dividend Yield

Feb 19

A Look Into Medistim's (OB:MEDI) Impressive Returns On Capital

Jan 21

Have Insiders Been Selling Medistim ASA (OB:MEDI) Shares?

Dec 27

Medistim (OB:MEDI) Has Rewarded Shareholders With An Exceptional 375% Total Return On Their Investment

Dec 10

Could The Market Be Wrong About Medistim ASA (OB:MEDI) Given Its Attractive Financial Prospects?

Nov 23

Earnings and Revenue Growth Forecasts

OB:MEDI - Analysts future estimates and past financials data (NOK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	595	125	N/A	N/A	1
12/31/2025	563	118	108	122	1
12/31/2024	539	107	70	83	1
3/31/2024	526	103	105	135	N/A
12/31/2023	521	104	83	113	N/A
9/30/2023	527	117	86	107	N/A
6/30/2023	519	116	74	96	N/A
3/31/2023	499	116	71	92	N/A
12/31/2022	486	114	92	113	N/A
9/30/2022	459	98	115	127	N/A
6/30/2022	444	92	126	138	N/A
3/31/2022	431	93	120	132	N/A
12/31/2021	418	91	116	127	N/A
9/30/2021	397	88	90	101	N/A
6/30/2021	378	84	63	73	N/A
3/31/2021	356	70	59	70	N/A
12/31/2020	356	69	63	74	N/A
9/30/2020	358	71	68	82	N/A
6/30/2020	360	74	78	91	N/A
3/31/2020	371	75	78	92	N/A
12/31/2019	357	70	67	80	N/A
9/30/2019	363	79	62	78	N/A
6/30/2019	355	73	58	74	N/A
3/31/2019	338	64	44	60	N/A
12/31/2018	323	57	39	56	N/A
9/30/2018	305	46	53	67	N/A
6/30/2018	303	48	47	61	N/A
3/31/2018	296	45	40	54	N/A
12/31/2017	296	48	N/A	62	N/A
9/30/2017	281	41	N/A	41	N/A
6/30/2017	274	39	N/A	36	N/A
3/31/2017	272	41	N/A	45	N/A
12/31/2016	263	39	N/A	30	N/A
9/30/2016	274	45	N/A	35	N/A
6/30/2016	268	45	N/A	37	N/A
3/31/2016	258	43	N/A	38	N/A
12/31/2015	250	40	N/A	45	N/A
9/30/2015	242	39	N/A	47	N/A
6/30/2015	233	37	N/A	48	N/A
3/31/2015	223	33	N/A	51	N/A
12/31/2014	214	31	N/A	49	N/A
9/30/2014	200	28	N/A	37	N/A
6/30/2014	193	24	N/A	37	N/A
3/31/2014	194	26	N/A	27	N/A
12/31/2013	190	27	N/A	26	N/A
9/30/2013	187	20	N/A	24	N/A
6/30/2013	187	32	N/A	18	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MEDI's forecast earnings growth (7.5% per year) is above the savings rate (2.1%).

Earnings vs Market: MEDI's earnings (7.5% per year) are forecast to grow slower than the Norwegian market (15% per year).

High Growth Earnings: MEDI's earnings are forecast to grow, but not significantly.

Revenue vs Market: MEDI's revenue (4.6% per year) is forecast to grow faster than the Norwegian market (1.7% per year).

High Growth Revenue: MEDI's revenue (4.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MEDI's Return on Equity is forecast to be high in 3 years time

Medistim Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Medistim ASA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Price target decreased by 10% to kr260

Consensus EPS estimates increase by 23%

Consensus forecasts updated

Price target decreased to kr300

Consensus EPS estimates increase by 12%

Recent updates

Medistim ASA Approves Dividend for the Year 2023, Payable on May 6, 2024

Medistim ASA Proposes Dividend

Medistim ASA Announces Board Changes

Medistim ASA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2023 earnings released: EPS: kr5.68 (vs kr6.25 in FY 2022)

CEO & President recently bought kr1.9m worth of stock

Medistim ASA to Report Q1, 2024 Results on Apr 25, 2024

One Medistim ASA (OB:MEDI) Analyst Has Been Cutting Their Forecasts

Price target decreased by 10% to kr260

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings released: EPS: kr1.80 (vs kr1.82 in 2Q 2022)

CEO & President recently sold kr10.0m worth of stock

Less than half of directors are independent

First quarter 2023 earnings released: EPS: kr1.41 (vs kr1.30 in 1Q 2022)

Upcoming dividend of kr4.50 per share at 1.6% yield

Independent Director recently bought kr301k worth of stock

Consensus EPS estimates increase by 23%

Full year 2022 earnings released: EPS: kr6.25 (vs kr4.99 in FY 2021)

Danske Bank A/S acquired a 5% stake in Medistim ASA.

Medistim ASA to Report First Half, 2023 Results on Aug 31, 2023

What Does Medistim ASA's (OB:MEDI) Share Price Indicate?

Third quarter 2022 earnings: Revenues miss analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Should You Be Adding Medistim (OB:MEDI) To Your Watchlist Today?

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Price target decreased to kr300

A Look At The Intrinsic Value Of Medistim ASA (OB:MEDI)

Investor sentiment improved over the past week

Consensus EPS estimates increase by 12%

First quarter 2022 earnings: EPS misses analyst expectations

Upcoming dividend of kr3.75 per share

Medistim (OB:MEDI) Is Increasing Its Dividend To kr3.75

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Medistim ASA Proposes Ordinary Dividend for 2021, Payable on 9 May 2022

Medistim (OB:MEDI) Is Paying Out A Larger Dividend Than Last Year

Investor sentiment deteriorated over the past week

Statutory Profit Doesn't Reflect How Good Medistim's (OB:MEDI) Earnings Are

Consensus EPS estimates fall by 20%

Medistim's (OB:MEDI) Shareholders Will Receive A Bigger Dividend Than Last Year

Independent Director recently bought kr104k worth of stock

Price target decreased to kr343

Medistim ASA Proposes Dividend

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

CEO & President recently bought kr4.4m worth of stock

Medistim (OB:MEDI) Is Reinvesting To Multiply In Value

Third quarter 2021 earnings released: EPS kr1.03 (vs kr0.79 in 3Q 2020)

Medistim (OB:MEDI) Might Become A Compounding Machine

Here's Why I Think Medistim (OB:MEDI) Might Deserve Your Attention Today

Second quarter 2021 earnings released: EPS kr1.88 (vs kr1.11 in 2Q 2020)

Chief Financial Officer recently sold kr6.6m worth of stock

Medistim ASA Announces the Launch of the Pay Per Procedure Functionality to Latest MiraQTM Platform in the US Market

Here's What Medistim's (OB:MEDI) Strong Returns On Capital Mean

First quarter 2021 earnings released: EPS kr1.20 (vs kr1.16 in 1Q 2020)

Medistim ASA Approves Dividend, Payable on May 7, 2021

Full year 2020 earnings released: EPS kr3.81 (vs kr3.87 in FY 2019)

Chairman recently sold kr179m worth of stock

Is Medistim ASA's(OB:MEDI) Recent Stock Performance Tethered To Its Strong Fundamentals?

Medistim ASA (OB:MEDI) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target raised to kr245

Full year 2020 earnings released: EPS kr3.81 (vs kr3.87 in FY 2019)

Revenue beats expectations, earnings disappoint

Here's What You Should Know About Medistim ASA's (OB:MEDI) 1.1% Dividend Yield

Universal-Investment-Luxembourg SA acquired a 5.07% stake in Medistim ASA (OB:MEDI).

New 90-day high: kr270

A Look Into Medistim's (OB:MEDI) Impressive Returns On Capital